+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group



Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group



Journal of Clinical Oncology 26(18): 2966-2972



Retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy are two adjuvant treatment options for patients with clinical stage I nonseminomatous germ cell tumors of the testis (NSGCT). Aim of this trial was to prove the advantage of one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy compared with RPLND in terms of recurrence. Between 1996 and 2005, 382 patients were randomly assigned to receive either RPLND (n = 191) or one course of BEP (n = 191) after orchidectomy. The primary study end point was the rate of recurrence. The trial was powered to detect a 7% reduction (from 10% to 3%) of recurrence with chemotherapy compared with surgery. After a median follow-up of 4.7 years, two and 15 recurrences were observed in the intention-to-treat population with chemotherapy and surgery, respectively (P = .0011). The difference in the 2-year recurrence-free survival rate between chemotherapy (99.46%; 95% CI, 96.20% to 99.92%) and surgery (91.87%; 95% CI, 86.87% to 95.02%) was 7.59% (95% CI, 3.13% to 12.05%). The hazard ratio to experience a tumor recurrence with surgery as opposed to chemotherapy was 7.937 (95% CI, 1.808 to 34.48). To our knowledge, this is the largest randomized trial investigating adjuvant treatment strategies in clinical stage I NSGCT, which showed the superiority of one course BEP over RPLND performed according to community standards to prevent recurrence. Although not standard treatment, one course of BEP is active in an unselected group of patients with clinical stage I disease and merits further investigation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055358534

Download citation: RISBibTeXText

PMID: 18458040

DOI: 10.1200/jco.2007.12.0899


Related references

One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): Results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German Testicular Cancer Study Group [GTCSG] Trial 01-94). Journal of Clinical Oncology 24(18_Suppl): 4512-4512, 2016

Randomised phase III trial comparing retroperitoneal lymph node dissection (RPLND) with one course of bleomycin, etoposide, cisplatin (BEP) chemotherapy in patients with stage I non-seminomatous germ cell tumour patients (NSGCT) - Updated results of auo trial 01/94. European Urology Suppl.s 7(3): 84, 2008

Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. Journal of Urology 169(5): 1710-1714, 2003

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Journal of Clinical Oncology 26(3): 421-427, 2008

Complications Of Post-Chemotherapy Retroperitoneal Lymph Node Dissection (Pcrplnd) In Advanced Nonseminomatous Germ Cell Tumors First Results Of The German Testicular Cancer Study Group. The Journal of Urology 183(4): e250-e251, 2010

The advantages of retroperitoneal lymph node dissection instead of initial chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors. Journal of Urology 153(4 Suppl. ): 244A, 1995

Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. Journal of Clinical Oncology 25(35): 5597-5602, 2007

Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of Clinical Oncology 21(8): 1505-1512, 2003

Primary retroperitoneal lymph node dissection for clinical low stage nonseminomatous germ cell testicular tumors. The Journal of Urology 179(4): 175, 2008

Laparoscopic retroperitoneal lymph node dissection for clinical Stage I nonseminomatous germ cell testicular tumors. Urology 54(6): 1064-1067, 1999

Results of retroperitoneal lymph node dissection and post operative adjuvant chemo therapy with dactinomycin in the treatment of retroperitoneal metastases of nonseminomatous testicular germ cell tumors. Cancer 51(6): 1076-1079, 1983

Mp10-09 Fifteen Years After Treatment With One Adjuvant Cycle Of Etoposide, Bleomycin And Cisplatin Chemotherapy Outcomes In Patients With High Risk Nonseminomatous Germ Cell Tumors Clinical Stage I. Extended Follow Up Of A Prospective Single Arm Clinical Trial Cohort. The Journal of Urology 191(4): e117-e118, 2014

Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. European Urology 69(3): 518-525, 2016

Is retroperitoneal lymph node dissection alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors at high risk for relapse?. Journal of Urology 159(5 Suppl. ): 49, 1998

Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. Journal of Urology 177(3): 937, 2007